Guardant ordered to pay $245m in DNA sequencing patent dispute
Guardant Health was ordered to pay $245.2m to TwinStrand Biosciences and the University of Washington for patent infringement. The ruling covers 11 products, including Guardant360 CDx, and includes damages, royalties, and interest. Guardant plans to appeal, while TwinStrand affirms its commitment to its intellectual property.
How this was made
The 30-second read
Why it matters
The $245.2M judgment, plus ongoing 6% royalty on sales through 2033, creates a sizable financial burden and may affect cash flow and valuation.
Market read
The ruling introduces a new, material liability for Guardant, likely influencing its stock price and raising awareness of IP risk in the biotech sector.
What to watch
Potential insurance coverage for legal liabilities and the ability to restructure royalty payments.
Background
Guardant Health provides liquid biopsy tests; the judgment stems from a long-running patent dispute over Duplex Sequencing technology.
Ticker impact
Guardant Health was ordered to pay $245.2M for patent infringement, a fresh legal judgment affecting its finances.
Potential short-term decline as investors price in the $245M penalty and ongoing royalty obligations.
The large, newly disclosed penalty and future royalty stream represent material financial impact.
Market effects
May weigh on other liquid biopsy and genomics companies as litigation risk is highlighted.
US biotech sector could see modest pressure.
Limited to companies with similar DNA sequencing patents.
Counterpoint
If Guardant successfully appeals, the penalty could be reduced, limiting downside.
Key entities
- CompanyGuardant Health
US-listed liquid biopsy provider (NASDAQ: GH).
- CompanyTwinStrand Biosciences
Patent holder of Duplex Sequencing technology.
- InstitutionUniversity of Washington
Co-owner of the patents underlying Duplex Sequencing.
